Top ▲
Target not currently curated in GtoImmuPdb
Target id: 2150
Nomenclature: phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha
Abbreviated Name: C2α/PIK3C2A
Family: Phosphatidylinositol-4-phosphate 3-kinase family, Phosphatidylinositol kinases
Gene and Protein Information ![]() |
||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 1686 | 11p15.1 | PIK3C2A | phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha | |
Mouse | - | 1686 | 7 61.62 cM | Pik3c2a | phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha | |
Rat | - | 1687 | 1 q34-q35 | Pik3c2a | phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha |
Database Links ![]() |
|
Alphafold | O00443 (Hs), Q61194 (Mm) |
BRENDA | 2.7.1.154 |
CATH/Gene3D | 1.10.1070.11, 2.60.40.150, 3.30.1520.10 |
ChEMBL Target | CHEMBL1075102 (Hs) |
Ensembl Gene | ENSG00000011405 (Hs), ENSMUSG00000030660 (Mm), ENSRNOG00000020479 (Rn) |
Entrez Gene | 5286 (Hs), 18704 (Mm), 361632 (Rn) |
Human Protein Atlas | ENSG00000011405 (Hs) |
KEGG Enzyme | 2.7.1.154 |
KEGG Gene | hsa:5286 (Hs), mmu:18704 (Mm), rno:361632 (Rn) |
OMIM | 603601 (Hs) |
Pharos | O00443 (Hs) |
RefSeq Nucleotide | NM_002645 (Hs), NM_011083 (Mm), NM_001108500 (Rn) |
RefSeq Protein | NP_002636 (Hs), NP_035213 (Mm), NP_001101970 (Rn) |
UniProtKB | O00443 (Hs), Q61194 (Mm) |
Wikipedia | PIK3C2A (Hs) |
Selected 3D Structures ![]() |
|||||||||||
![]() |
|
Enzyme Reaction ![]() |
||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||
|
Immuno Process Associations | ||
|
1. Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, Sabatini DM, Gray NS. (2011) Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem, 54 (5): 1473-80. [PMID:21322566]
2. Parkinson GN, Vines D, Driscoll PC, Djordjevic S. (2008) Crystal structures of PI3K-C2alpha PX domain indicate conformational change associated with ligand binding. BMC Struct Biol, 8: 13. [PMID:18312637]